Multidrug-resistant tuberculosis in côte d'ivoire from 1995 to 2016: Results of national surveys

N’guessan, K.; Ouassa, Timothée; Dean, Anna; Alagna, Riccardo; Adagra, G.D.; Ibode, Valeri; Cirillo, Daniela María; Kouakou, J.

doi:10.1556/1886.2018.00001

Cited by 10 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The estimated figures are 3.5 and 16% MDR/RR-TB, respectively, among new and retreatment cases in the country (5). This correlates with a 10-year national survey which found 4.5 and 22% RR-TB among new and previously treated TB cases in the country (35). A cohort of 81 MDR-TB patients monitored in a pneumology unit, faced debilitating side effects leading to dropouts (39.2%), deaths (15.2%), diverse attacks (30.4%), and only 5% cured (38).…”

Section: Côte D'ivoiresupporting

confidence: 78%

“…Data on DR-TB in WA are scanty which reflect diagnostic limitation but not actual epidemiologic situation (31). Drugresistant TB including but not limited to MDR and XDR is an emerging public health problem in WA with several countries reporting different prevalence over the years (7,(32)(33)(34)(35). A collaborative DR-TB surveillance among nine WA countries by the West African Network for Tuberculosis, AIDS and Malaria (WANETAM) showed that the WHO estimates are almost always below the actual incidence (Figure 1) (33).…”

Section: Prevalence and Distribution Of Drug-resistant Tuberculosis I...mentioning

confidence: 99%

See 1 more Smart Citation

Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control

Otchere,

Asante-Poku,

Akpadja

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

Drug-resistant (DR) tuberculosis (TB) is a major public health concern globally, complicating TB control and management efforts. West Africa has historically faced difficulty in combating DR-TB due to limited diagnostic skills, insufficient access to excellent healthcare, and ineffective healthcare systems. This has aided in the emergence and dissemination of DR Mycobacterium tuberculosis complex (MTBC) strains in the region. In the past, DR-TB patients faced insufficient resources, fragmented efforts, and suboptimal treatment outcomes. However, current efforts to combat DR-TB in the region are promising. These efforts include strengthening diagnostic capacities, improving access to quality healthcare services, and implementing evidence-based treatment regimens for DR-TB. Additionally, many West African National TB control programs are collaborating with international partners to scale up laboratory infrastructure, enhance surveillance systems, and promote infection control measures. Moreso, novel TB drugs and regimens, such as bedaquiline and delamanid, are being introduced to improve treatment outcomes for DR-TB cases. Despite these obstacles, there is optimism for the future of DR-TB control in West Africa. Investments are being made to improve healthcare systems, expand laboratory capacity, and support TB research and innovation. West African institutions are now supporting knowledge sharing, capacity building, and resource mobilization through collaborative initiatives such as the West African Network for TB, AIDS, and Malaria (WANETAM), the West African Health Organization (WAHO), and other regional or global partners. These efforts hold promise for improved diagnostics, optimized treatment regimens, and provide better patient outcomes in the future where drug-resistant TB in WA can be effectively controlled, reducing the burden of the disease, and improving the health outcomes of affected individuals.

show abstract

Section: Côte D'ivoiresupporting

confidence: 78%

Section: Prevalence and Distribution Of Drug-resistant Tuberculosis I...mentioning

confidence: 99%

Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control

Otchere,

Asante-Poku,

Akpadja

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…In nearby Burkina Faso, levels of 3.4% in new cases similar to what we detected, but very high levels in previously treated patients (50.5%) have been reported [ 19 ]. Similarly, in Côte d’Ivoire, the proportion of patients with rifampicin resistance was estimated to be 4.6% (95% CI: 2.4–6.7) and 22% (95% CI: 13.7–30.3), respectively, for new and previously treated patients [ 20 ]. In Tanzania, the prevalence of any resistance among new and previously treated patients was 8.3% and 20%, respectively [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

The burden of drug resistance tuberculosis in Ghana; results of the First National Survey

et al. 2021

View full text Add to dashboard Cite

Resistance to Tuberculosis drugs has become a major threat to the control of tuberculosis (TB) globally. We conducted the first nation-wide drug resistance survey to investigate the level and pattern of resistance to first-line TB drugs among newly and previously treated sputum smear-positive TB cases. We also evaluated associations between potential risk factors and TB drug resistance. Using the World Health Organization (WHO) guidelines on conducting national TB surveys, we selected study participants from 33 health facilities from across the country, grouped into 29 clusters, and included them into the survey. Between April 2016 and June 2017, a total of 927 patients (859 new and 68 previously treated) were enrolled in the survey. Mycobacterium tuberculosis complex (MTBC) isolates were successfully cultured from 598 (65.5%) patient samples and underwent DST, 550 from newly diagnosed and 48 from previously treated patients. The proportion of patients who showed resistance to any of the TB drugs tested was 25.2% (95% CI; 21.8–28.9). The most frequent resistance was to Streptomycin (STR) (12.3%), followed by Isoniazid (INH) (10.4%), with Rifampicin (RIF), showing the least resistance of 2.4%. Resistance to Isoniazid and Rifampicin (multi-drug resistance) was found in 19 (3.2%; 95% CI: 1.9–4.9) isolates. Prevalence of multidrug resistance was 7 (1.3%; 95% CI: 0.5–2.6) among newly diagnosed and 12 (25.0%; 95% CI: 13.6–39.6) among previously treated patients. At both univariate and multivariate analysis, MDR-TB was positively associated with previous history of TB treatment (OR = 5.09, 95% CI: 1.75–14.75, p = 0.003); (OR = 5.41, 95% CI: 1.69–17.30, p = 0.004). The higher levels of MDR-TB and overall resistance to any TB drug among previously treated patients raises concerns about adherence to treatment. This calls for strengthening existing TB programme measures to ensure a system for adequately testing and monitoring TB drug resistance.

show abstract

“…The rate of 14.5% found among PTPs in this study is similar to what was found in Botswana [1] (13%). Higher levels were reported in the nearby countries of Democratic Republic of the Congo (17%) [1], Ivory Coast (22%) [15], and in Ghana (27.7%) [16]. The prevalence of RR-TB was highest among patients failing a category I regimen and patients with TB relapse.…”

Section: Discussionmentioning

confidence: 99%

Multidrug-resistant tuberculosis in Burkina Faso from 2006 to 2017: Results of national surveys

Diandé

Badoum

Combary

et al. 2019

EuJMI

View full text Add to dashboard Cite

Setting A survey of the prevalence of drug-resistant tuberculosis (DR-TB) in new and previously treated patients (PTPs) was performed in Burkina Faso from 2016 to 2017. Design In this cross-sectional survey, a structured questionnaire was administered to eligible smear-positive patients in all 86 diagnostic and treatment centers of the country to collect their socio-demographic characteristics and medical histories. Their sputa were tested using the Mycobacterium tuberculosis/rifampicin (MTB/RIF) Xpert assay. Those which were found to be positive for TB and rifampicin-resistant were also tested with GenoType MTBDRplus2.0 and MTBDRsl2.0. Univariate and multivariate logistic regressions were performed to determine risk factors associated with rifampicin resistance. Results Of the 1140 smear-positive patients enrolled, 995 new and 145 PTPs were positive for MTB complex by Xpert. Of these, 2.0% (20/995, 95% confidence interval (CI): 1.1–2.9) of the new cases and 14.5% (95% CI: 14.2–20.2) of the PTPs were resistant to rifampicin; 83% of them has multidrug-resistant tuberculosis (MDR-TB). None were pre-extensively drug-resistant TB (pre-XDR-TB) or XDR-TB. Only the previous treatment was significantly associated with rifampicin resistance, p < 0.0001. Conclusion Similar to global trends, rifampicin resistance was significantly higher in patients with prior TB treatment (14.5%) than in naïve patients (2.0%). These percentages are slightly below the global averages, but nonetheless suggest the need for continued vigilance. Extending the use of Xpert testing should strengthen the surveillance of DR-TB in Burkina Faso.

show abstract

Multidrug-resistant tuberculosis in côte d'ivoire from 1995 to 2016: Results of national surveys

Cited by 10 publications

References 7 publications

Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control

Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control

The burden of drug resistance tuberculosis in Ghana; results of the First National Survey

Multidrug-resistant tuberculosis in Burkina Faso from 2006 to 2017: Results of national surveys

Contact Info

Product

Resources

About